FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
Purpose
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Condition
- Mesial Temporal Lobe Epilepsy
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male or Female, age ≥18 to 75 2. Focal seizures, clinically defined as unilateral MTLE 3. Has failed to achieve seizure control despite adequate trials of at least 2 ASDs at appropriate doses 4. Currently on stable doses (at least 1 month) of approved ASDs 5. Single seizure focus confirmed within one hippocampus 6. Seizure frequency averages ≥4 per 28-day period, including at least 2 clinical focal seizures per 28-day period with objective manifestations or more severe types, over the 6 months prior to the Screening Visit. 7. Considered (by Investigator) to be a candidate for temporal lobectomy (TL) or Laser Interstitial Thermal Therapy (LITT) following evaluation at a qualified epilepsy surgery program (National Association of Epilepsy Centers [NAEC] Level 4).
Exclusion Criteria
- Epilepsy due to other and/or progressive neurologic disease 2. Evidence of seizure focus outside of the hippocampus or evidence of seizures of non- focal origin. 3. Significant other medical conditions which would impair safe participation 4. History of status epilepticus in the year prior to screening. A history of cluster seizures is permitted. 5. Primary or secondary immunodeficiency 6. Suicide attempts in the past year 7. Severe psychiatric disorders 8. Prior lobectomy or LITT procedure 9. MRI indicating potential malignant lesion 10. Pregnancy, or currently breastfeeding.
Study Design
- Phase
- Phase 1/Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- This is a two-phase study. Phase 1 is an open-label, single arm, sequential dose escalation. Phase 2 is a parallel, randomized, 2-arm, sham controlled study.
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
- Masking Description
- This is a two-phase study. Phase 1 is open-label and unmasked. Phase 2 is blinded with participant, part of investigator team, and outcomes assessor masked to treatment assignment.
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental NRTX-1001 (Phase 1) |
Up to 28 subjects |
|
|
Experimental NRTX-1001 (Phase 2) |
Up to 20 subjects |
|
|
Sham Comparator Sham Comparator(Phase 2) |
Up to 10 subjects. |
|
Recruiting Locations
Phoenix, Arizona 85054
Tucson, Arizona 85724-5023
Little Rock, Arkansas 72205
Los Angeles, California 90033
Los Angeles, California 90095
Orange, California 92868
Palo Alto, California 94304
Sacramento, California 95817
San Diego, California 92037
San Francisco, California 94143
Aurora, Colorado 80045
Chicago, Illinois 60612
Chicago, Illinois 60637
Iowa City, Iowa 52242
New Orleans, Louisiana 70121
Boston, Massachusetts 02215
Detroit, Michigan 48201
Omaha, Nebraska 68198
New York, New York 10016
Syracuse, New York 13210
Charlotte, North Carolina 28204
Durham, North Carolina 27710
Winston-Salem, North Carolina 27157
Portland, Oregon 97239
Philadelphia, Pennsylvania 19107
Houston, Texas 77030
Salt Lake City, Utah 84108
Milwaukee, Wisconsin 53226
More Details
- NCT ID
- NCT05135091
- Status
- Recruiting
- Sponsor
- Neurona Therapeutics
Detailed Description
Subjects will undergo a single CT or MRI-guided intracerebral administration of human interneurons that secrete the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), into the temporal lobe region of the brain where the seizures are thought to arise. NRTX-1001 is intended to suppress the onset and spread of seizures. Safety, tolerability, and effects on reducing seizure frequency and epilepsy disease symptoms will be assessed at quarterly intervals for 2 years after the administration of NRTX-1001. After the two-year period, subjects will be followed with quarterly phone calls and annual visits in years 3 through 5, and then annual visits in years 6 through 15. Subjects will be placed on an immunosuppressant medication regimen for a duration of one year to partially suppress the subjects' immune system to promote the intended long-term persistence of NRTX-1001. This immunosuppressant medication is intended to be discontinued after the first year; however, the NRTX-1001 cells are intended to persist long-term.